Entity of excessive daytime sleepiness in Parkinson’s disease
Objective: To examine frequency and reasons of excessive daytime sleepiness (EDS) in patients with Parkinson’s disease (PD). Background: Neurodegeneration and dopaminergic medications are known to…Prevalence and factors related to orthostatic hypotension and orthostatic intolerance in recently-diagnosed, drug-naïve Parkinson’s disease patients
Objective: To explore the prevalence and factors related to orthostatic hypotension (OH) and orthostatic intolerance (OI) in recently diagnosed drug-naïve PD patients from the Parkinson’s…Alterations of Blood Pressure Circadian Rhythm in Alpha-Synucleinopathies
Objective: To analyze the blood pressure (BP) circadian rhythm in Parkinson’s disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF), evaluating possible differences…The prevalence of supine hypertension and nocturnal hypertension and the difference of blood pressure in each sleep position in Parkinson’s disease
Objective: This study aimed to determine the prevalence, associated factors of SH/NH and to identify relationships between blood pressure (BP) and sleep position in PD…Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study
Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension
Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…Effects of orthostatic hypotension and supine hypertension on cognition in Parkinson’s disease
Objective: The purpose of this study was to investigate the correlation of hemodynamic parameters and cognition in patients with PD. Background: Cognitive impairment is common…Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure
Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…Predictor of progressive mild cognitive impairment in patients with Parkinson’s disease.
Objective: To clarify clinical features of patients with progressive mild cognitive impairment patients (MCI) in Parkinson’s disease (PD-MCI). Background: Non-demented PD subjects have MCI and…Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results
Objective: To assess the impact of droxidopa on fear of falling in patients with symptomatic neurogenic orthostatic hypotension (nOH) in 2 studies. Background: nOH results…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- Next Page »